艾久久

关于NMN研究的文献

  • 念兔55
  • 2022-06-17 01:53:12

​​NMN：人类衰老干预技术革命中的定海神针

2013年12月，哈佛大学医学院大卫·辛克莱尔（David Sinclair）教授在世界权威杂志《Cell》上发表“用NMN提升细胞内NAD+含量一周后，小鼠寿命延长了30%”的研究成果，首次公开证实NAD+前体NMN可以逆转衰老、延长寿命。这项研究轰动世界，也从此开启了NMN在衰老抑制和衰老干预领域一骑绝尘的局面。

截止目前，《Nature》、《Science》、《Cell》三大国际权威期刊已发表100余篇NMN及其代谢物NAD+的相关报道，展示了NMN在延缓衰老、修复DNA损伤、调节代谢、保护心脏等领域的显著效果。

2021年4月23日，《Science》重磅上线了全球首个NMN人体临床试验结果，进一步确认了NMN对人体的安全性和有效性，成为人类抗衰新时代的里程碑。

关于NMN研究的文献

参考文献

  1. Vincenzo Carafa, Dante Rotili, Mariantonietta Forgione, Francesca Cuomo, Enrica Serretiello, Gebremedhin Solomon Hailu, Elina Jarho, Maija Lahtela-Kakkonen, Antonello Mai, Lucia Altucci. Sirtuin functions and modulation: from chemistry to the clinic. Clin epigenetics, 2016; DOI: 10.1186/s13148-016-0224-3.
  2. Niels J. Connell, Riekelt H. Houtkooper, Patrick Schrauwen. NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia, 2019; DOI: 10.1007/s00125-019-4831-3.
  3. Julia Evangelou.  “Natural compound reduces signs of aging in healthy mice.” ScienceDaily.com.  27 October, 2016.  Web. 16 January. 2020.
  4. Henryk Jęśko, Przemysław Wencel, Robert P. Strosznajder, Joanna B. Strosznajder. Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders. Neurochem Res, 2017; DOI: 10.1007/s11064-016-2110-y.
  5. Ann Katrin-Hopp, Patrick Grüter, Michael O. Hottiger. Regulation of Glucose Metabolism by NAD+ and ADP-Ribosylation. Cells, 2019; DOI: 10.3390/cells8080890.
  6. Vamshi K.C. Nimmagadda, Tapas K. Makar, Krish Chandrasekaran, Avinash Rao Sagi, Jayanta Ray, James W. Russell, Christopher T Bever Jr. SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review. J Neuroimmunol, 2017; DOI: 10.1016/j.jneuroim.2016.07.007.
  7. Katalin Sas, Elza Szabó, László Vécsei. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Molecules, 2018; DOI: 10.3390/molecules23010191.
  8. Yue Yang, Anthony A. Sauve. NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta, 2016; DOI: 10.1016/j.bbapap.2016.06.014.
  9. Jun Yoshino, Kathryn F. Mills, Myeong Jin Yoon, Shin-ichiro Imai. Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice.  Cell Metab, 2011; DOI: 10.1016/j.cmet.2011.08.014.
  10. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab, 2016; DOI: 10.1016/j.cmet.2016.09.013.
  11. Shuang Zhou, Xiaoqiang Tang, Hou-Zao Chen. Sirtuins and Insulin Resistance. Front Endocrinol (Lausanne), 2018; DOI: 10.3389/fendo.2018.00748.
  12. Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, 2019 Nov 2]. Endocr J. 2019;10.1507/endocrj.EJ19-0313. doi:10.1507/endocrj.EJ19-0313
  13. 文章来源：https://www.nmn.cn/what-is-nmn
    14. ​​​​